Background: Second-generation antipsychotics (SGAs) are used to treat mental illness in children but have side effects including weight gain, dyslipidemia, hypertension, and risk for type 2 diabetes. These side effects are well-known risk factors for cardiovascular disease. However, little is known about the cardiovascular health of SGA-treated children.

Methods: Cross-sectional study of children (aged 6-18 years) with mental illness that were SGA-treated (n=47) or SGA-naïve (n=37), and control children (n=83, no mental illness). Anthropometrics and a fasting blood sample were collected. Subclinical indicators of atherosclerosis were assessed. Central pulse-wave velocity (PWV) by standard M-mode echocardiography and Doppler tracing, an indicator of arterial stiffness, and carotid intima-media thickness (cIMT) were assessed.

Results: SGA-treated children had greater BMI z-scores (p<0.001) and higher (p<0.001) prevalence of overweight/obesity (BMI ≥85th percentile for age and sex) than SGA-naïve and control children. SGA-treated children had higher fasting plasma insulin (p=0.016) and 21.7% had hyperinsulinemia (fasting insulin ≥100pmol/L) compared to 12.9% of SGA-naïve children. No differences in fasting glucose or circulating lipids were observed. Hypertension was observed in 14.9% of SGA-treated children, compared to 5.4% of SGA-naïve and 6.0% of control children. SGA-treated (p=0.002) and SGA-naive children (p<0.001) had higher PWV compared to controls (adjusted for age, sex, BMI, systolic blood pressure). No effect of SGAs or mental health diagnosis on cIMT was observed.

Conclusion: Children with mental illness have greater arterial stiffness than control children.

Disclosure

A.M. Henderson: None. N. Islam: None. G.G. Sandor: None. C. Panagiotopoulos: Advisory Panel; Self; Dexcom, Inc. A.M. Devlin: None.

Funding

British Columbia Mental Health & Substance Use Services

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.